8:50 Chairman’s Welcome & Opening Remarks

9:00 Keynote Presentation: Peptide Drugs In Metabolic Medicine

• Introducing anti-obesity peptides
• Discussing obesity monotherapy: Davalintide and novel Y-family mimetics
• Introducing Integrated Neurohormonal Therapy for Obesity (INTO)
• Exploring how peptide combination therapies can be designed into a single molecule: Peptide Hybrids
• Defining the trade-offs for peptide biologics as treatments for metabolic diseases

Dr. Michael Hanley
Chief Scientific Officer
Amylin Pharmaceuticals Inc

9:45 GLP-1 Secretagogues In The Treatment Of Type 2 Diabetes

• Providing an overview of G protein–coupled receptors and their role in GLP-1 release
• Discussing recent advances in the discovery of TGR5 agonists
• Understanding disease modifying effects in improving or preserving b-cell function

11:00 FGF21: Pharmacological Characterization And Its Receptor Interaction And Activation Mechanism

• Providing an overview of FGF21 in treating metabolic disorders
• Discussing recent FGF21 pharmacology studies
• Understanding the FGF21 receptor requirement and specificity
• Exploring recent discovery in FGF21 receptor interaction an activation mechanism

Dr. Junming Yie
Senior Scientist, Department of Metabolic Disorders
Amgen Inc.

11:45 ZDSD Rat: A Model For Diabetes, Metabolic Syndrome, And Obesity Without Leptin Or Leptin Receptor Mutations

• The ZDSD rat is a model for obesity, insulin resistance, metabolic syndrome and diabetes with a normal leptin axis
• The disease conditions expressed in the ZDSD more closely resemble the human situation when compared to other animal models
• The obesity and diabetes in the ZDSD rat can be modulated with diet
• The obesity and diabetes in the ZDSD rat can be treated with standard pharmaceuticals
• The ZDSD rat expresses the bone, renal and other complications seen in diabetes

Dr. Richard G. Peterson
EVP Research & Development
PreClinOmics Inc.

1:30 New Therapeutic Approaches --- De-Stressing Metabolic Disease

• Examining cellular stress events and inflammation in metabolic disease
• Discussing the role of endoplasmic reticulum adaptive function and JNK activity in pathophysiology
• Identifying novel approaches to modulate these critical biological events
• Understanding the discovery of small molecule drug candidates

Dr. Teo Uysal
President & CEO
Syndexa Pharmaceuticals

2:15 Development Of Novel Small Molecule Sirtuin1 Activators For The Treatment Of Type 2 Diabetes

• Discussing the discovery of small molecule activators of Sirt1
• Understanding novel metabolic and anti-inflammatory role for Sirt1 activators
• Exploring preclinical efficacy in animal models of Type 2 Diabetes
• Presenting phase 1 Data with SRT2104

Dr. James L. Ellis
Vice President, Preclinical Research
Sirtris Pharmaceuticals, a GSK Company

3:30 GPR119: Multifaceted Regulation Of Glucose Homeostasis By Novel Agonists

• Providing an overview of GPR119 regulation of incretin and insulin release
• Exploring endogenous lipid regulators of GPR119
• Discussing key aspects of GPR119 agonist development
• Discovering efficacy in chronic rodent models of Type 2 Diabetes

Dr. James Leonard
Sr. Director, Metabolic Disorders
Arena Pharmaceuticals Inc.

4:15 Discovery Of PF-04620110: A Selective DGAT-1 Inhibitor For The Treatment Of Type 2 Diabetes

• Examining drug design in the context of DGAT-1 chemical landscape/pharmacophore analyses
• Preclinical evaluation DGAT-1 inhibition on diabetic and obesity endpoints in a chronic setting
• Understanding integration of safety derisking strategies in the early lead generation and optimization stages
• Discussing Phase I pharmacokinetic/safety results in the context of preclinical predictions

Dr. Robert Dow
Associate Research Fellow
CVMD Chemistry, Pfizer Global Research and Development